IL117036A0 - Methods of inhibiting effects of il-6 - Google Patents

Methods of inhibiting effects of il-6

Info

Publication number
IL117036A0
IL117036A0 IL11703696A IL11703696A IL117036A0 IL 117036 A0 IL117036 A0 IL 117036A0 IL 11703696 A IL11703696 A IL 11703696A IL 11703696 A IL11703696 A IL 11703696A IL 117036 A0 IL117036 A0 IL 117036A0
Authority
IL
Israel
Prior art keywords
methods
inhibiting effects
inhibiting
effects
Prior art date
Application number
IL11703696A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL117036A0 publication Critical patent/IL117036A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
IL11703696A 1995-02-06 1996-02-05 Methods of inhibiting effects of il-6 IL117036A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38473095A 1995-02-06 1995-02-06

Publications (1)

Publication Number Publication Date
IL117036A0 true IL117036A0 (en) 1996-06-18

Family

ID=23518514

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11703696A IL117036A0 (en) 1995-02-06 1996-02-05 Methods of inhibiting effects of il-6

Country Status (14)

Country Link
EP (1) EP0724879A2 (enExample)
JP (1) JPH10513470A (enExample)
KR (1) KR19980701933A (enExample)
CN (1) CN1173819A (enExample)
AU (1) AU708374B2 (enExample)
CA (1) CA2212232A1 (enExample)
CZ (1) CZ246597A3 (enExample)
FI (1) FI973235A0 (enExample)
HU (1) HUP9801829A3 (enExample)
IL (1) IL117036A0 (enExample)
NO (1) NO973609L (enExample)
WO (1) WO1996024356A1 (enExample)
YU (1) YU6996A (enExample)
ZA (1) ZA96897B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046588A2 (en) 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6025373A (en) * 1997-04-22 2000-02-15 Eli Lilly And Company Methods for reducing fibrinogen
KR20020009383A (ko) 1998-04-01 2002-02-01 우에노 도시오 축합 티오펜 유도체 및 이의 유도체를 유효 성분으로 하는약제
US6960577B2 (en) 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
ES2207982T3 (es) * 1998-12-30 2004-06-01 Signal Pharmaceuticals, Inc. Compuestos y metodos para la modulacion de receptores estrogenicos.
ES2156550B1 (es) * 1999-04-19 2002-02-01 Univ Navarra Publica Derivados de benzo(b) tiofenosulfonamida-1,1-dioxido y su uso como agentes antineoplasicos.
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
RU2005125043A (ru) * 2003-01-06 2006-01-27 Уайт (Us) Применение модуляторов альфа-рецепторов эстрогена для лечения рассеянного склероза

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
TW303299B (enExample) * 1993-07-22 1997-04-21 Lilly Co Eli
US5574047A (en) * 1993-12-21 1996-11-12 Eli Lilly And Company Methods of inhibiting imperfect tissue repair
US5708009A (en) * 1993-12-21 1998-01-13 Eli Lilly And Company Methods of inhibiting myeloperoxidase activity
US5521198A (en) * 1993-12-21 1996-05-28 Eli Lilly And Company Methods of inhibiting autoimmune diseases
US5567820A (en) * 1994-05-20 1996-10-22 Eli Lilly And Company Glucopyranoside benzothiophenes

Also Published As

Publication number Publication date
EP0724879A2 (en) 1996-08-07
FI973235A7 (fi) 1997-08-05
KR19980701933A (ko) 1998-06-25
NO973609L (no) 1997-09-11
ZA96897B (en) 1997-08-05
WO1996024356A1 (en) 1996-08-15
NO973609D0 (no) 1997-08-05
FI973235L (fi) 1997-08-05
EP0724879A3 (enExample) 1996-09-11
MX9705940A (es) 1997-10-31
HUP9801829A3 (en) 1999-10-28
JPH10513470A (ja) 1998-12-22
CA2212232A1 (en) 1996-08-15
AU4916396A (en) 1996-08-27
AU708374B2 (en) 1999-08-05
HUP9801829A2 (hu) 1999-05-28
FI973235A0 (fi) 1997-08-05
CN1173819A (zh) 1998-02-18
CZ246597A3 (cs) 1998-06-17
YU6996A (sh) 1999-03-04

Similar Documents

Publication Publication Date Title
PL327569A1 (en) Promedications of thrombosin inhibitors
PL324527A1 (en) Cyclic inhibitors of gmp-specific phosphodisterase
PL321759A1 (en) Novel thrombosin inhibitors
HUP9802252A3 (en) Sustained-release formulation of d-threo-methylphenidate
AU7168696A (en) Inhibitors of regulatory pathways
IL112031A0 (en) Methods of inhibiting autoimmune diseases
HUP9601524A2 (en) Prodrugs of paclytaxel-derivatives
HU9403666D0 (en) Methods of inhibiting breast disorders
IL116924A0 (en) Preparation of n-aryl- and n-hetarylhydroxylamines
IL122338A0 (en) Methods of inhibiting phagocytosis
IL118574A0 (en) Methods of inhibiting melanoma
SG43387A1 (en) Magnetic of device
AU4916396A (en) Methods of inhibiting effects of il-6
GB9621852D0 (en) Inhibition of scale
PL327147A1 (en) Method of obtaining dihydropyrimidinones
PL326978A1 (en) Method of obtaining dioxyaza bicyclohexanes
IL117786A (en) Preparation of alpha-bisoximes
IL117277A0 (en) Methods of inhibiting ovarian cancer
SG64924A1 (en) Inhibiting photodecompostion of 3-substituted-2- oxindoles
PL312826A1 (en) Method of obtaining dilthiazeme
GB9521681D0 (en) Improved method of manufacture
AU7399298A (en) Methods of inhibiting corrosion using N-haloazoles
PL322204A1 (en) Method of obtaining 2-ethylantraquinone
ZA962440B (en) Destressing of railtracks
GB9521509D0 (en) Inhibition of scale